Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease
This study is currently recruiting participants.
Verified May 2013 by AxioMed Spine Corporation
Sponsor:
AxioMed Spine Corporation
Information provided by (Responsible Party):
AxioMed Spine Corporation
ClinicalTrials.gov Identifier:
NCT01763619
First received: January 4, 2013
Last updated: May 16, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will collect clinical and radiographic data on the Freedom Cervical Disc to monitor the device's safety and performance as part of a post-market evaluation.
| Condition | Intervention |
|---|---|
|
Symptomatic Cervical Degenerative Disc Disease (DDD) From C3-C7 |
Device: Freedom Cervical Disc |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease |
Further study details as provided by AxioMed Spine Corporation:
Primary Outcome Measures:
- Safety of FCD [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]Monitor the safety (operative and post-operative adverse events through 6-months) of the FCD.
- Performance of FCD [ Time Frame: 6 months ] [ Designated as safety issue: No ]Monitor the performance (radiographic evaluation of segmental non-fusion and device function) of the FCD through 6-months post-operative period.
Secondary Outcome Measures:
- Incidence of AEs [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]Examine the incidence of adverse events including device revision, removal or supplemental fixation through the 2-years post-operative period.
- Neck/Arm Pain [ Time Frame: 2 years ] [ Designated as safety issue: No ]Examine changes in neck and arm pain throughout the 2-years post-operative period.
- Neurological function [ Time Frame: 2 years ] [ Designated as safety issue: No ]Examine changes in subject neurological function throughout the 2-years post-operative period.
- Subject Function [ Time Frame: 2 years ] [ Designated as safety issue: No ]Examine changes in subject function throughout the 2-years post-operative period.
- Radiographic Measurements [ Time Frame: 2 years ] [ Designated as safety issue: No ]Examine changes in radiographic measurements of the target, adjacent and cervical segment levels from discharge through the 2-years.
- Examine AEs [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]Examine all adverse events throughout the 2-years post-operative period
| Estimated Enrollment: | 50 |
| Study Start Date: | February 2013 |
| Estimated Study Completion Date: | January 2015 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Freedom Cervical Disc | Device: Freedom Cervical Disc |
Eligibility| Ages Eligible for Study: | 21 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Skeletally mature males or females, aged 21 to 65 years old, inclusive.
- Single, or adjacent, 2-level degenerative disc disease at C3-C7, inclusive.
- Subject is a surgical candidate for an anterior approach to the cervical spine.
- Minimum of 6 weeks of unsuccessful conservative treatment.
- Subject with at least moderate preoperative pain and functional impairment
- Subject is mentally and physically able to comply with protocol, postoperative compliance instructions, and follow-up schedule through 2-years.
- Subject must understand and sign the written Informed Consent form.
Exclusion Criteria:
- Subject with axial neck pain only who does not demonstrate concurrent arm pain or progressive neurological deterioration (specifically numbness or muscle weakness in the arm).
- An active infection at the operative site or active systemic infection at the time of surgery.
- Known or suspected allergy to titanium, polyurethane, cobalt, chromium, molybdenum or silicone.
- Previous spinal fusion at the involved, or adjacent, cervical level(s).
- Congenital or acquired structural defect at the operative levels (s) or their immediately adjacent level(s).
- Significant osteoporosis in the cervical spine.
- The investigator should assess if the subject has any of the following conditions at the index or adjacent level(s) which excludes the subject from study participation:
- Cervical facet degeneration of the involved C3-C7 levels.
- Previous trauma to, or fusion in, the C3-C7 levels.
- Cervical instability at the index level(s) on neutral lateral or flexion/extension x-rays.
- Radiographic findings of a fused or total collapsed disc.
- Significant global cervical kyphosis (≥15º on Cobb angle measurement) or significant reversal of lordosis.
- Female of childbearing potential, pregnant, breast feeding, or interested in becoming pregnant in the next two years
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01763619
Contacts
| Contact: Neal Defibaugh | 2165875566 | ndefibaugh@axiomed.com |
| Contact: Courtney Maguire | 2165875566 | cmaguire@axiomed.com |
Locations
| Germany | |
| Klinik Fleetinsel Hamburg | Recruiting |
| Hamburg, Germany, 20459 | |
| Contact: Michael Muschik, MD | |
| Principal Investigator: Michael Muschik, MD | |
| Stadtisches Klinikum Karlsruhe | Recruiting |
| Karlsruhe, Germany, 76133 | |
| Contact: George Kiriyanthan, MD | |
| Principal Investigator: George Kiriyanthan, MD | |
| Switzerland | |
| Klinik St. Anna | Recruiting |
| Luzern, Switzerland, CH-6006 | |
| Contact: Oliver Hausmann, MD | |
| Principal Investigator: Oliver Hausmann, MD | |
| Spine Center Rischke | Recruiting |
| Zurich, Switzerland, CH 8001 | |
| Contact: Burkhard Rischke, MD | |
| Principal Investigator: Burkhard Rischke, MD | |
Sponsors and Collaborators
AxioMed Spine Corporation
More Information
No publications provided
| Responsible Party: | AxioMed Spine Corporation |
| ClinicalTrials.gov Identifier: | NCT01763619 History of Changes |
| Other Study ID Numbers: | PR-300 |
| Study First Received: | January 4, 2013 |
| Last Updated: | May 16, 2013 |
| Health Authority: | Scotland: Scottish Executive Health Department Switzerland: Ethikkommission Germany: Ethics Commission |
Keywords provided by AxioMed Spine Corporation:
|
Cervical DDD DDD degenerative disc disease C3-C7 |
Additional relevant MeSH terms:
|
Spinal Diseases Intervertebral Disk Degeneration Bone Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on May 16, 2013